Background: Published studies about passive smoking and cervical cancer have found inconsistent results. Hence, the present meta-analysis was performed to assess this association. Methods: A systematical search was performed to identify eligible cohort and case–control studies in PubMed, Scopus, Elsevier ScienceDirect, and Web of Science databases (up to March, 2018). The quality of included studies was assessed by the Newcastle–Ottawa quality scale (NOS). The random effects model (REM) was used to calculate the pooled odds ratio (ORs). Subgroup and sensitivity analyses were performed. Publication bias was assessed by funnel plot, using Begg's test and Egger's test. Results: Around 14 eligible studies were included for analysis, which included a total of 384,995 participants. The pooled ORs of passive smoking with cervical cancer risk was 1.70 (95% CI: 1.40–2.07, I2 = 64.3%). Subgroups stratified by continent, study design, quality score, and cervical cancer types/phases suggested that the result was robust. For instance, the pooled ORs for the cohort and case–control studies was 1.37 (95% CI: 1.16–1.62, I2 = 0%) and 2.09 (95% CI: 1.52–2.89, I2 = 76.6%), respectively. The pooled ORs ranged from 1.61 (95%CI: 1.34–1.92) to 1.77 (95%CI: 1.44–2.16) after one study was removed each time in the sensitivity analyses, indicating that the result was stable. Publication bias was detected by funnel plot and Egger's tests. The recalculated ORs were 1.33 (95% CI: 1.21–1.47). Conclusions: This meta-analysis provides evidence that passive smoking is associated with an increased risk of cervical cancer.
1 January 2015 in Diabetes Research and Clinical Practice
The aim of this study was to evaluate the global scientific output of neurotoxicity of nanoparticles (NPs) and explore their hot spots and research trends. Articles about the neurotoxicity of NPs between 2008 and 2017 were taken from the Web of Science Core Collection database. The VOSviewer was used to analyze annual publications, countries/institutions, funding agencies, research objects, major journals, and international cooperation. The reference co-citation map and keywords were used to analyze the mechanisms of neurotoxicity of NPs. Six hundred and forty-one eligible studies were included for analysis, and the annual publications increased with time in the past decade. Based on the bibliometric analysis, China and the United States were the main countries in this field. Metals and metal oxides were the main types of NPs. Cell, rat, and mouse were the primary research objects of NPs. The main research hot spots might focus on the pathogenesis of NPs, such as oxidative stress and apoptosis. This study will help researchers understand the research status, hot spots, and trends of neurotoxicity of NPs.
1 October 2011 in International Journal of Oral Science
Tumors often have DNA repair defects, suggesting additional inhibition of other DNA repair pathways in tumors may lead to synthetic lethality. Accumulating data demonstrate that DNA repair‐defective tumors, in particular homologous recombination (HR), are highly sensitive to DNA‐damaging agents. Thus, HR‐defective tumors exhibit potential vulnerability to the synthetic lethality approach, which may lead to new therapeutic strategies. It is well known that poly (adenosine diphosphate (ADP)‐ribose) polymerase (PARP) inhibitors show the synthetically lethal effect in tumors defective in BRCA1 or BRCA2 genes encoded proteins that are required for efficient HR. In this review, we summarize the strategies of targeting DNA repair pathways and other DNA metabolic functions to cause synthetic lethality in HR‐defective tumor cells.
Inadequate sustained immune activation and tumor recurrence are major limitations of radiotherapy (RT), sustained and targeted activation of the tumor microenvironment can overcome this obstacle. Here, by two models of a primary rat breast cancer and cell co-culture, we demonstrated that valproic acid (VPA) and its derivative (HPTA) are effective immune activators for RT to inhibit tumor growth by inducing myeloid-derived macrophages and polarizing them toward the M1 phenotype, thus elevate the expression of cytokines such as IL-12, IL-6, IFN-γ and TNF-α during the early stage of the combination treatment. Meanwhile, activated CD8+ T cells increased, angiogenesis of tumors is inhibited, and the vasculature becomes sparse. Furthermore, it was suggested that VPA/HPTA can enhance the effects of RT via macrophage-mediated and macrophage-CD8+ T cell-mediated anti-tumor immunity. The combination of VPA/HPTA and RT treatment slowed the growth of tumors and prolong the anti-tumor effect by continuously maintaining the activated immune response. These are promising findings for the development of new effective, low-cost concurrent cancer therapy.